(Boursier.com) — Leading the SRD on Wednesday, Transgene soared by more than 20% to 2.17 euros at the start of the session in Paris! The biotech and its partner BioInvent International have announced the selection of their abstract describing preclinical results obtained with BT-001, a co-engineered oncolytic virus, for a poster presentation at the 2022 annual conference of the American Association for Cancer Research (AACR) . The poster will show that BT-001, a product in clinical development based on Transgene’s proprietary oncolytic vector and encoding BioInvent’s proprietary anti-CTLA-4 antibody and cytokine GM-CSF, has the potential to provide greater benefit therapeutic than systemically administered anti-CTLA-4 antibodies. The conference will be held face-to-face in New Orleans, LA, from April 8-13.
At the same time, Transgene will present a poster with new promising initial Phase I data with TG4050, its individualized vaccine targeting tumor mutations specific to each patient (neoantigens). The abstract has been accepted for a late-breaking session and will be available on the AACR website and app from April 8. The first product from the myvac platform, TG4050 uses the power of NEC’s artificial intelligence (AI) technologies. It is currently being evaluated in two multicenter Phase I trials in patients with ovarian cancer and head and neck cancer.
©2022 Boursier.com